List view / Grid view
Drug Target Review
Filter the results
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
Scientists report how editing a portion of stem cells with CRISPR-Cas9 is sufficient for long-term reactivation of therapeutic haemoglobin.
Researchers have newly found that protein CD24 acts as a defensive signal and is used by cancer cells to protect themselves.
New study sheds light on how the TP53 gene becomes mutated and how those mutations can help predict clinical outlooks for cancer.
Researchers have discovered a new combination therapy to treat drug-resistant acute lymphoblastic leukaemia, tested in pre-clinical trials.
New discovery makes it possible to design new therapies to replace alpha-synuclein's function in people with Parkinson's disease.
Salk scientists discover a pair of enzymes that drive non-small-cell lung cancer by promoting inflammation which could inform the development of new therapies.
Newly developed HDO-antimiR could lead to new ways to treat diseases which are caused by malfunctioning miRNAs.
Researchers have extended the life of heart segments from 24 hours to six days, enabling pre-clinical trials to experiment on these new models for longer periods of time.
Scientists have created the first completely artificial protein switch that can be ‘programmed’ to modify gene expression.
An antibody has been developed to block a protein secreted by the cells surrounding ovarian and pancreatic cancer tumours.